Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VNDA 
Vanda Pharmaceuticals Inc (VNDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VNDA (1-star) is a SELL. SELL since 2 days. Profits (-10.53%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.34% | Avg. Invested days 23 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 314.86M USD | Price to earnings Ratio - | 1Y Target Price 10.43 |
Price to earnings Ratio - | 1Y Target Price 10.43 | ||
Volume (30-day avg) 657505 | Beta 0.77 | 52 Weeks Range 3.98 - 6.75 | Updated Date 03/30/2025 |
52 Weeks Range 3.98 - 6.75 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -8.59% | Operating Margin (TTM) -23.09% |
Management Effectiveness
Return on Assets (TTM) -3.64% | Return on Equity (TTM) -3.02% |
Valuation
Trailing PE - | Forward PE 30.3 | Enterprise Value -94612359 | Price to Sales(TTM) 1.32 |
Enterprise Value -94612359 | Price to Sales(TTM) 1.32 | ||
Enterprise Value to Revenue 0.59 | Enterprise Value to EBITDA 12.91 | Shares Outstanding 58308100 | Shares Floating 52531556 |
Shares Outstanding 58308100 | Shares Floating 52531556 | ||
Percent Insiders 3.16 | Percent Institutions 76.98 |
Analyst Ratings
Rating 4 | Target Price 10.43 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vanda Pharmaceuticals Inc
Company Overview
History and Background
Vanda Pharmaceuticals Inc. was founded in 2003. It focuses on developing and commercializing innovative therapies to address unmet medical needs.
Core Business Areas
- Sleep Disorders: Development and commercialization of products for sleep disorders, primarily Hetlioz for Non-24 hour sleep-wake disorder.
- Psychiatric Disorders: Development and commercialization of products for psychiatric disorders.
- Gastrointestinal Disorders: Development and commercialization of products for gastrointestinal disorders.
Leadership and Structure
Mihael H. Polymeropoulos, M.D. is the Chairman, President and CEO. The organizational structure consists of various departments including R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Hetlioz (tasimelteon): Used to treat Non-24 hour sleep-wake disorder in totally blind individuals and for sleep disorders in children with autism spectrum disorder. Competitors include melatonin supplements and other sleep aids, but Hetlioz is a branded prescription medication with a specific indication. 2023 revenue was $208 million. Market share within the Non-24 is significant, although the exact percentage is not publicly available. Non-24 is a small and rare disorder.
- Fanapt (iloperidone): An atypical antipsychotic medication used to treat schizophrenia. Competitors include other atypical antipsychotics such as risperidone, quetiapine, and olanzapine. 2023 revenue was $76 million. The market share for Fanapt in the antipsychotic market is relatively small.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. There is a growing demand for specialized therapies for niche indications.
Positioning
Vanda Pharmaceuticals focuses on niche markets with unmet medical needs, particularly in sleep disorders and psychiatric conditions. Its competitive advantage lies in its specialized focus and intellectual property.
Total Addressable Market (TAM)
The total addressable market for sleep disorders and psychiatric conditions is substantial, estimated to be billions of dollars. Vanda targets specific subsegments within these broader markets.
Upturn SWOT Analysis
Strengths
- Specialized focus on niche markets
- Proprietary products with patent protection
- Experienced management team
- Established commercial infrastructure
Weaknesses
- Reliance on a limited number of products
- High dependence on Hetlioz sales
- Limited pipeline depth
- Legal challenges can be costly
Opportunities
- Expansion into new indications for existing products
- Acquisition of complementary products or technologies
- Strategic partnerships with larger pharmaceutical companies
- Geographic expansion into international markets
Threats
- Generic competition
- Regulatory changes
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- ALKS
- JAZZ
- TEVA
Competitive Landscape
Vanda's competitive advantage lies in its specialized focus on niche markets, which allows it to avoid direct competition with larger pharmaceutical companies in many cases. However, it faces competition from generic drugs and other branded products in certain therapeutic areas.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Vanda's growth has been primarily driven by the sales of Hetlioz and Fanapt.
Future Projections: Future growth depends on the successful development and commercialization of new products and the expansion of existing products into new markets. Analysts' estimates vary depending on their assumptions about the company's pipeline.
Recent Initiatives: Vanda has been focused on expanding the use of Hetlioz in new patient populations and pursuing strategic partnerships.
Summary
Vanda Pharmaceuticals is a specialty pharmaceutical company with a focus on niche markets. Its primary revenue driver is Hetlioz. While it has shown some promise in specific areas, its reliance on a limited number of products and past financial setbacks present risks. Future success depends on pipeline development and strategic execution.
Similar Companies
- ALKS
- JAZZ
- TEVA
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vanda Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2006-04-12 | Founder, President, CEO & Chairman of The Board Dr. Mihael H. Polymeropoulos M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 368 | Website https://www.vandapharma.com |
Full time employees 368 | Website https://www.vandapharma.com | ||
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.